NASDAQ: ELABPmgc Holdings Inc Stock
$2.14-0.03 (-1.38%)
Updated Jun 27, 2025
ELAB Price
$2.14
Fair Value Price
N/A
Market Cap
$2.94M
52 Week Low
$1.95
52 Week High
$839.86
P/E
0.08x
P/B
0.36x
P/S
-4.1x
PEG
N/A
Dividend Yield
N/A
Revenue
-$614.56k
Earnings
-$6.46M
Gross Margin
72.5%
Operating Margin
933.15%
Profit Margin
1,050.7%
Debt to Equity
0.09
Operating Cash Flow
-$5M
Beta
1.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ELAB Overview
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ELAB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important ELAB news, forecast changes, insider trades & much more!
ELAB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELAB is good value based on its earnings relative to its share price (0.08x), compared to the US market average (32.24x)
P/E vs Market Valuation
ELAB is good value based on its earnings relative to its share price (0.08x), compared to the US Biotechnology industry average (-117.68x)
P/E vs Industry Valuation
ELAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more ELAB due diligence checks available for Premium users.
Valuation
ELAB fair value
Fair Value of ELAB stock based on Discounted Cash Flow (DCF)
Price
$2.14
Fair Value
$0.50
Overvalued by
327.42%
ELAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.08x
Industry
-117.68x
Market
32.24x
ELAB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ELAB is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ELAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.36x
Industry
4.43x
ELAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELAB's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.6M
Profit Margin
0%
ELAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ELAB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.9M
Liabilities
$760.3k
Debt to equity
0.09
ELAB's short-term assets ($6.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELAB's short-term assets ($6.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.3M
Investing
-$215.3k
Financing
$2.9M
ELAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELAB vs Biotech Stocks
Pmgc Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.